title: [Modified CHOP therapy in patients with non-Hodgkin's lymphoma].
abstract: From July 1983 to December 1989, 31 previously untreated patients with non-Hodgkin's lymphoma were treated with modified CHOP regimen (cyclophosphamide 300 mg/m2 on day 1, aclacinomycin 40 mg/m2 on day 1, vincristine 0.7 mg/m2 on day 1 and prednisolone 40 mg/m2 on days 1-5). The therapy was repeated at 2-week intervals. The complete response rate was 66.7% for clinical stage (CS) II according to the Ann Arbor criteria, 60.0% for CS III and 33.3% for CS IV, respectively. The 5-year survival rate was 100% for CS II, 36.6% for CS III and 34.6% for CS IV, respectively. Clinical effects of modified CHOP regimen were almost the same as those of other therapies including adriamycin from the standpoint of 5-year survival rate. On the other hand, the myelosuppression accompanying modified CHOP therapy was not severe. Only one patient had a white blood count below 1,000/microliters during 6 courses of the therapy. It is thought that this regimen is useful to enhance the quality of life of patients because of no severe complications such as myelosuppression.
authors.affiliation: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyu-shu, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Misago
authors.forename: S
authors.initials: S
authors.lastname: Chiba
authors.forename: J
authors.initials: J
authors.lastname: Tsukada
authors.forename: K
authors.initials: K
authors.lastname: Nakata
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Nagata
authors.forename: N
authors.initials: N
authors.lastname: Mori
authors.forename: A
authors.initials: A
authors.lastname: Wake
authors.forename: R
authors.initials: R
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Kikuchi
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: C011157:aclacinomycins; D014750:Vincristine; D015250:Aclarubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone